SKL2001-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESKL2001Cat.No.:HY-101085CASNo.:909089-13-0分?式:C??H??N?O?分?量:286.29作?靶點(diǎn):Wnt;β-catenin作?通路:StemCell/Wnt儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:≥96.66mg/mL(337.63mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM3.4930mL17.4648mL34.9296mL5mM0.6986mL3.4930mL6.9859mL10mM0.3493mL1.7465mL3.4930mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(8.73mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(8.73mM);ClearsolutionBIOLOGICALACTIVITY?物活性SKL2001Wnt/β-catenin信號(hào)通路的激動(dòng)劑，具有抗腫瘤活性。SKL2001通過破壞Axin/β-catenin相互作?，穩(wěn)定細(xì)胞內(nèi)β-catenin。IC50&TargetWnt/β-catenin[1]體外研究SKL2001isanagonistoftheWnt/β-cateninpathway,andalsoupregulatestheexpressionofAxin2,adownstreamtargetoftheWnt/β-cateninpathway,butshowsnoeffectonNF-κB,p53reporteractivityandGSK-3βactivity.SKL2001causesosteoblastdifferentiation(20and40μM)andsuppressespreadipocytedifferentiation(5,10,and30μM)viatheactivationoftheWnt/β-cateninpathway.SKL2001(5,10,and30μM)stabilizesintracellularβ-cateninin3T3-L1cells[1].SKL2001(40μM)significantlyinhibitstheproliferationofHCT116spheroidsindependentlyofcytotoxicityandtheinhibitionisreversible;SKL2001cuasescellcyclearrestinHCT116spheroids.SKL2001(40μM)enhancesround-shapespheroidformationandE-cadherinexpression[2].PROTOCOLCellAssay[1]ST2cellsareculturedonglasschamberslidesandthentreatedwithDMSOorSKL2001for15h.Aftertreatment,thecellsarewashedwithPBS,fixedwith4%formaldehyde,permeabilizedin0.3%TritonX-100,andblockedin4%bovineserumalbuminfor1h.Thecellsarestainedwithanti-β-cateninantibodyandthenanalyzedbyconfocalmicroscopyusingamicroscope[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?JAdvRes.26November2021.?ExpMolMed.2022Sep1.?CellDeathDis.2020Aug18;11(8):644.?BiomedPharmacother.2020Sep;129:110414.?BiomedPharmacother.2019May16;116:108974.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].GwakJ,etal.Smallmolecule-baseddisruptionoftheAxin/β-cateninproteincomplexregulatesmesenchymalstemcelldifferentiation.ellRes.2012Jan;22(1):237-47.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[2].OhashiW,etal.SKL2001suppressescoloncancerspheroidgrowththroughregulationoftheE-cadherin/β-Catenincomplex.BiochemBiophysResCommun.2017Nov25;493(3):1342-1348.McePdfHeightCaution:Producthasnotbeenfullyvalid